- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05766553
Effects of Mindfulness Meditation in Virtual Reality on Craving and Smoking Cessation (VIREAMIND)
Investigators seek to propose a non-drug therapeutic alternative, namely a mindfulness meditation protocol based on virtual reality training in order to induce progressive modifications of various indicators of craving.
The study hypothesis is that the practice of mindfulness meditation in a virtual reality environment reduces the craving induced by cues and stress and therefore ultimately smoking relapse.
The main objective of the protocol will be to demonstrate that mindfulness meditation can reduce long-term relapse (continuous cessation (> 30 days) of smoking cessation).
The participants will be randomized into two groups: the experimental group will perform six virtual reality sessions in a multisensory cabin at the rate of one session per week; the control group will be prescribed the gold standard treatment (nicotine patches and chewing gum).
Participants will be seen again at three and six months to assess whether or not there has been a smoking relapse.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nematollah JAAFARI
- Phone Number: +33 5 16 52 61 18
- Email: nemat.jaafari@ch-poitiers.fr
Study Locations
-
-
-
Iteuil, France
- Recruiting
- Cabinet Médical
-
Contact:
- Marc Besnier, MD
- Email: marc.besnier@hotmail.fr
-
Poitiers, France
- Recruiting
- Centre Hospitalier Henri Laborit
-
Contact:
- Nemat Jaafari, PU-PH
- Email: nemat.jaafari@ch-poitiers.fr
-
Poitiers, France
- Recruiting
- Cabinet médical des Couronneries
-
Contact:
- Lakshmipriya LE BONHEUR, MD
- Email: lak.lebonheur@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any patient consuming 10 to 40 cigarettes per day
- Woman or man aged 18 to 75 inclusive
- Substance use disorder according to the DSM5 classification
- Benefit from social security or benefit from it through a third party in accordance with French law on research involving the human person
- Having signed the informed consent form after having received written information.
Exclusion Criteria:
- Disabling cognitive disorders
- Patient under 18 or over 75 years old.
- Patient with a psychological disorder or a psychiatric pathology requiring specialized follow-up
- Patient with addiction to another product.
- Cardiological pathologies that could compromise the participation of patients, detected by an ECG (only for patients who will be randomized in the experimental group).
- Advanced pulmonary, renal, and hepatic diseases, or any unstable and serious medical conditions that could compromise the patient's participation in the study, subject to the judgment of the doctor
- Pregnant or breastfeeding woman
- Simultaneous participation in another trial
- Employee of the investigator or of the clinical trial site
- Patients protected by law
- Patients who do not speak the French language
- People not covered by state health insurance
- Patients who in the opinion of the investigator are unable to complete the questionnaires
- Patient claustrophobic or anxious about using the cabin
- Patient allergic to a molecule present in nicotine substitutes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventional Group
Patients in this arm will have 6 sessions of virtual reality in a pod (1 session per week). Patients will then have a visit at day 90 and day 180. |
The first two sessions provide guided training in relaxation and mindfulness through immersion in a virtual forest environment for the first session, and in a virtual beach environment for the second.
Sessions 3 and 4 present environments with addiction-related stimuli (Cues).
The session 3 consists of a walk through the virtual street environment, buying a bottle of water from the store, and then ordering a coffee from a virtual bar.
The session 4 takes place in a virtual party environment in an apartment: people smoke and drink alcohol in the living room, the session consists of sitting with them, then going to the kitchen to get a water bottle.
Sessions 5 and 6 present stressful environments.
Session 5 consists of a virtual parachute jump.
The 6th session takes place in a virtual airplane environment, which will encounter turbulence.
|
Active Comparator: Control group
Patients in this arm will receive the gold standard of treatment for tobacco cessation (nicotine patches and chewing gum) from day 0 (inclusion visit) to day 90. Patients will then have a visit at day 90 and day 180. |
Participants in this group will be prescribed a Gold Standard smoking cessation treatment with nicotine patches adapted to their consumption and 4mg nicotine chewing gum for a period of 3 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse at 3 months
Time Frame: 3 months
|
Relapse of patients by declaring their consumption at 3 months.
|
3 months
|
Relapse at 6 months
Time Frame: 6 months
|
Relapse of patients by declaring their consumption at 6 months.
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
- 2022-A02004-39
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use Disorder
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
Harvard School of Public Health (HSPH)Beacon Communities; The Community BuildersEnrolling by invitationTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Second Hand Tobacco SmokeUnited States
-
University of California, San FranciscoNational Institute on Minority Health and Health Disparities (NIMHD)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of California, San FranciscoTobacco Related Disease Research ProgramCompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Smoking, Tobacco | Smoking, CigaretteUnited States
-
New York State Psychiatric InstituteTerminatedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Nicotine Dependence | Cigarette Smoking | Tobacco Dependence | Nicotine Use Disorder | Smoking, CigaretteUnited States
-
Rutgers, The State University of New JerseyNational Institute on Drug Abuse (NIDA)CompletedSchizophrenia | Schizoaffective Disorder | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use CessationUnited States
-
University of PennsylvaniaFood and Drug Administration (FDA)Completed
-
University of Kansas Medical CenterCompletedTobacco Use Disorder/Cigarette SmokingUnited States
-
Ottawa Hospital Research InstituteCompletedTobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence
Clinical Trials on Virtual reality pod
-
Centre Hospitalier Henri LaboritRecruiting
-
Institut National de la Santé Et de la Recherche...Not yet recruitingSchizophrenia | Bipolar Disorder
-
Eskisehir Osmangazi UniversityNot yet recruiting
-
The University of Hong KongRecruiting
-
Universidad Rey Juan CarlosCompleted
-
University of PennsylvaniaNot yet recruitingEnd Stage Kidney Disease
-
National University of MalaysiaRecruitingPleural EffusionMalaysia
-
Stanford UniversityTerminatedConversion Disorder | Non-epileptic Seizures | Functional Neurological Disorder | Functional Movement Disorder | Psychogenic Movement DisorderUnited States
-
University of WashingtonNational Institutes of Health (NIH); University of Texas; National Institute...Completed
-
Centre Hospitalier Universitaire de Saint EtienneInstitut de Cancérologie de la Loire; Gustave Roussy, Cancer Campus, Grand... and other collaboratorsTerminated